Anthony R Howlett

Author PubWeight™ 10.42^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.	Mol Cancer Ther	2003	2.07
2	The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.	Oncogene	2004	1.78
3	SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.	Cancer Res	2003	1.53
4	The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion.	Mol Cell Biol	2003	1.52
5	Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.	Cancer Chemother Pharmacol	2010	1.03
6	SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.	Cancer Chemother Pharmacol	2009	0.93
7	Adventitial microvessel formation after coronary stenting and the effects of SU11218, a tyrosine kinase inhibitor.	J Am Coll Cardiol	2006	0.90
8	Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin.	Neoplasia	2003	0.81